EP 1

EQS-News: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Retrieved on: 
Tuesday, December 26, 2023
BioNTech, CVAC, Federal court, Patent, Federal Patent Court (Germany), Messenger, COVID-19, CureVac, Bird, Vaccine, Justice, Sąd rejonowy, COVID-19 vaccine, EP 1, Intellectual property, LLP

CureVac will appeal before the German Federal Court of Justice.

Key Points: 
  • CureVac will appeal before the German Federal Court of Justice.
  • The ruling represents a first decision on validity in ongoing patent litigation between CureVac and BioNTech SE in Germany, which involves a total of eight CureVac intellectual property rights.
  • “We consider the patent court’s decision unfortunate also in view of the positive preliminary opinion on EP 1 857 122 B1 the court provided earlier this year.
  • The decision is only one of many that will be made regarding the use of CureVac’s intellectual property in the development of Comirnaty®.

DGAP-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update

Retrieved on: 
Thursday, August 18, 2022
CMOS, Trial of the century, Cancer, Clinical trial, GSK, Research, Pfizer, Patient, CMO, Contract, DE, RNA, Operating cost, BioNTech, Immune system, Efficiency, Pharmacovigilance, Disease, FLU, Omicron, Technology, Sale, EP 1, Partnership, GMP, CureVac, Safety, Novartis, Nasdaq, RNA transfection, CVAC, Senior, Judiciary, Roche, Therapy, COVID-19, Degenerative disease, Acquisition, Program, Vaccine, Virus, Vaccination, Goal, Cros, Genomics, Genentech, U1, Infection, Protein, Medicine, CureVac COVID-19 vaccine, Adult, Pharmaceutical industry, Fine chemical, Online gambling, Cryptocurrency

In the second quarter of 2022, the wind-down costs related to our first-generation vaccine candidate, CVnCoV, still impacted our financial position but continue to decrease as we conclude our remaining commitments, said Pierre Kemula, Chief Financial Officer of CureVac.

Key Points: 
  • In the second quarter of 2022, the wind-down costs related to our first-generation vaccine candidate, CVnCoV, still impacted our financial position but continue to decrease as we conclude our remaining commitments, said Pierre Kemula, Chief Financial Officer of CureVac.
  • Moving into the second half of 2022, we are further broadening our mRNA technology platform and advancing our programs in prophylactic vaccines as well as executing on our core strategy in oncology.
  • CureVac is delivering on its previously announced 2022 clinical development program in prophylactic vaccines by initiating a Phase 1 study with the modified COVID-19 mRNA vaccine candidate CV0501.
  • In the first quarter of 2022, CureVac received a 10 million milestone payment related to the start of the seasonal influenza clinical trial.